Working… Menu

Adverse Event Scale in Patients With Epilepsy (aEscape) - A European Survey for Physicians With Epilepsy Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00394927
Recruitment Status : Completed
First Posted : November 2, 2006
Last Update Posted : July 19, 2012
International Bureau for Epilepsy
Information provided by:
UCB Pharma

Brief Summary:
The purpose of the survey is to explore through a structured interview and patient examination the rate and distribution of neurological and systemic adverse effects related to antiepileptic treatment. Adverse effects and considerations to modify the therapy will be assessed in pediatric and adult patients with controlled as well as uncontrolled epilepsy with different seizure types

Condition or disease

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1000 participants
Observational Model: Cohort
Official Title: A Multicenter, Non-interventional Surveillance Study to Evaluate the Adverse Effects of Antiepileptic Drug Treatment in Patients With Epilepsy
Study Start Date : April 2007
Actual Primary Completion Date : August 2007
Actual Study Completion Date : August 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Epilepsy

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   4 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with confirmed diagnosis of epilepsy requiring anti-epileptic treatment and which are already receiving daily anti-epileptic treatment

Inclusion Criteria:

  • Male and female patients from the age of 4 years
  • Confirmed diagnosis of epilepsy requiring AED treatment
  • Patients already receiving daily AED treatment as a monotherapy or a polytherapy with maximum 2 AEDs within the terms of marketing authorization with the following medications: Carbamazepine, Clobazam, Clonazepam, Gabapentin, Lamotrigine, Levetiracetam, Oxcarbazepine, Phenobarbital, Phenytoin, Pregabalin, Tiagabine, Topiramate, Valproate, Zonisamide
  • Treatment must be stable for at least 3 months prior to assessment
  • Absence of other severe and/or uncontrolled symptomatic chronic illness

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00394927

  Show 54 Study Locations
Sponsors and Collaborators
UCB Pharma
International Bureau for Epilepsy
Layout table for investigator information
Study Director: Sonja Buyle, M.D. UCB Pharma

Layout table for additonal information Identifier: NCT00394927     History of Changes
Other Study ID Numbers: N01228
First Posted: November 2, 2006    Key Record Dates
Last Update Posted: July 19, 2012
Last Verified: July 2012
Keywords provided by UCB Pharma:
Adverse Effects
AntiEpileptic Drug treatment
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases